A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer.

被引：4
|
作者：
Soliman, Hatem Hussein
Minton, Susan E.
Ismail-Khan, Roohi
Han, Hyo S.
Vahanlan, Nicholas N.
Ramsey, William Jay
Kennedy, Eugene
Link, Charles J.
Sullivan, Daniel
Antonia, Scott Joseph
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] NewLink Genet, Ames, IA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps3124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3124
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of liposomal doxorubicin (Caelix) and docetaxel as first line treatment in patients with metastatic breast cancer.
    Morabito, A
    Fanelli, M
    Gilberti, S
    Vitale, S
    Arena, MG
    Biondi, E
    Gattuso, D
    Massidda, B
    Gasparini, G
    ANNALS OF ONCOLOGY, 2000, 11 : 42 - 42
  • [32] Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
    Cortes, Javier
    Baselga, Jose
    Im, Young-Hyuck
    Ross, Graham
    Clark, Emma
    Knott, Adam
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Phase I/II study of docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer.
    Tsai, JY
    Berkenblit, A
    Akerman, P
    Nadeem, A
    Rathore, R
    Harrington, D
    Roye, D
    Stuart, K
    Kennedy, TA
    Safran, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 322S - 322S
  • [34] A phase II study of bi-weekly docetaxel as first-line therapy for metastatic breast cancer.
    Durna, L. N.
    Yeon, C. H.
    Bosserman, L. D.
    Allison, M.
    Hu, E.
    Tchekmedyian, N. S.
    Srivastava, N.
    Ngo, D.
    Lin, L. S.
    Classen, S.
    Slamon, D. J.
    Pegram, M. D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S280 - S280
  • [35] Phase I study of liposomial doxorubicin (Caelix) and docetaxel as first line treatment in patients with metastatic breast cancer.
    Gasparini, G
    Morabito, A
    Fanelli, M
    Gilberti, S
    Vitale, S
    Arena, MG
    Biondi, E
    Gattuso, D
    Massidda, B
    ANNALS OF ONCOLOGY, 2000, 11 : 28 - 28
  • [36] Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study
    Humphreys, A
    Dent, J
    Rodwell, S
    Crawford, SM
    Joffe, JK
    Bradley, C
    Dodwell, D
    Perren, TJ
    BRITISH JOURNAL OF CANCER, 2004, 90 (11) : 2131 - 2134
  • [37] Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study
    A C Humphreys
    J Dent
    S Rodwell
    S M Crawford
    J K Joffe
    C Bradley
    D Dodwell
    T J Perren
    British Journal of Cancer, 2004, 90 : 2131 - 2134
  • [38] A phase 2 randomized trial of the 100 pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data
    Tang, S-C
    Montero, A.
    Munn, D.
    Link, C.
    Vahanian, N.
    Kennedy, E.
    Soliman, H.
    CANCER RESEARCH, 2016, 76
  • [39] Safety profile of docetaxel in older patients with metastatic breast cancer.
    Aapro, MS
    Olsen, SR
    Alakl, M
    Murawsky, M
    Hurria, A
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S129 - S129
  • [40] Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer
    Chia, Stephen
    Dent, Susan
    Ellard, Susan
    Ellis, Peter M.
    Vandenberg, Ted
    Gelmon, Karen
    Powers, Jean
    Walsh, Wendy
    Seymour, Lesley
    Eisenhauer, Elizabeth A.
    CLINICAL CANCER RESEARCH, 2009, 15 (02) : 708 - 713
12345